A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Cytarabine
Related studies linked through entity extraction aliases.
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML.
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE3
Epacadostat, Cladribine and Cytarabine (ECC) in AML
- Status
- WITHDRAWN
- Phase
- PHASE1
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS
- Status
- COMPLETED
- Phase
- PHASE1
Epacadostat, Idarubicin and Cytarabine (EIC) in AML
- Status
- WITHDRAWN
- Phase
- PHASE1
Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE3
RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT
- Status
- RECRUITING
- Phase
- PHASE2
RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT
- Status
- UNKNOWN
- Phase
- PHASE2
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML
- Status
- UNKNOWN
- Phase
- PHASE3
CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML
- Status
- UNKNOWN
- Phase
- PHASE3
Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations
- Status
- UNKNOWN
- Phase
- PHASE2